TNBIOTCGrain Mill ProductsFiscal year ends December 31

Tanke Biosciences Corp

Financials through Q3 FY2013, quarter ended Sep 30, 2013Last filing: 10-Q on Nov 14, 2013

$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $399.72K
P/E (TTM): –
Dividend yield: –

Tanke Biosciences Corp income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	29	24	20	–
Cost of Revenue	19	15	13	–
Gross Profit	9.94	8.77	7.40	–
Research & Development	0.29	0.25	–	–
General & Administrative	2.57	4.49	0.83	–
Operating Income	4.53	1.74	4.37	–
Interest Expense	1.45	1.36	0.10	–
Interest & Investment Income	0.30	0.10	0.00	–
Pretax Income	0.60	-2.45	4.28	–
Income Tax Expense	0.83	0.68	0.58	–
Net Income incl. Noncontrolling Interests	-0.23	-3.14	3.69	2.58
Minority Interest in Earnings	-0.02	0	0.96	–
Net Income	-0.21	-3.14	2.74	–
EPS (Basic)(per share)	-0.02	-0.24	0.34	–
EPS (Diluted)(per share)	-0.02	-0.24	0.34	–
Shares Outstanding (Basic, Weighted)(shares)	13	13	11	–
Shares Outstanding (Diluted, Weighted)(shares)	13	13	11	–
EBITDA	5.17	2.14	4.51	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2013

Profitability, TTM

Gross margin: 32.3%
Operating margin: -0.2%
Net margin: -7.1%
Return on equity, FY2012: -1.3%

Financial strength

Current ratio: 1.61
Debt to equity: 0.12
Debt to assets: 6.5%
Cash to current liabilities: 41.3%

Valuation

P/E ratio: –
Price to sales: 0.02
Price to book: 0.03
Dividend yield: –